Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $46.71 Average Price Target from Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have been assigned a consensus recommendation of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $46.71.

Several research firms recently commented on APLS. The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research note on Tuesday, December 17th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $26.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, January 29th. Wells Fargo & Company decreased their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price objective on the stock. Finally, Scotiabank dropped their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th.

Apellis Pharmaceuticals Trading Down 0.5 %

APLS stock opened at $28.53 on Friday. The business has a 50 day simple moving average of $31.68 and a two-hundred day simple moving average of $32.41. Apellis Pharmaceuticals has a 1-year low of $24.34 and a 1-year high of $71.90. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -14.05 and a beta of 0.96. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00. Following the completion of the transaction, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at approximately $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Caroline Baumal sold 2,816 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now directly owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,002 shares of company stock worth $1,800,119. 6.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC boosted its position in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after buying an additional 758 shares in the last quarter. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $27,000. True Wealth Design LLC purchased a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at about $27,000. Signaturefd LLC increased its position in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares during the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $56,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).